The sulfated polysaccharides dextran sulfate and heparin have proved to be potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) in vitro.
ular weights correlated well with their anticoagulant activity.
On the other hand, with dextran sulfates of low molecular weight (5000, 8000) a significant inhibitory effect on HIV-1 was achieved at a concentration that was not markedly inhibitory to the blood coagulation process. Dextran sulfate and heparin were not inhibitory to HIV-1 reverse transcriptase unless they were used at concentrations in excess of those that inhibited HIV-1 replication. They were highly effective against HIV-1 replication even when present only during the 2-hr virus adsorption period. Studies using radiolabeled HIV-1 virions indicated that dextran sulfate and heparin inhibit virus adsorption to the host cells.
The urgent need for an effective chemotherapy for the acquired immunodeficiency syndrome (AIDS), which is caused by human T-cell lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) (1, 2) , now termed human immunodeficiency virus type 1 (HIV-1), has prompted the search for selective anti-HIV agents. Suramin has been shown to inhibit the replication of HIV-1 in cell culture (3) and in AIDS patients (4) , and 3'-azido-3'-deoxythymidine (commonly called azidothymidine or AZT) has been proven to improve the clinical and immunological status of patients with AIDS and AIDS-related complex (5, 6) . The target of azidothymidine is the viral reverse transcriptase (7) , and the phosphorylated products of azidothymidine may be held responsible for the bone marrow suppression that is often associated with the administration of this compound (8) .
It has recently been reported that the sulfated polysaccharides dextran sulfate and heparin are highly selective inhibitors of HIV-1 replication in vitro (9, 10) . Polyanionic substances were, in fact, suggested by De Clercq (11) as potential anti-HIV-1 agents because oftheir putative effect on the virus adsorption process. Studies have now been undertaken to determine the specificity of the anti-HIV-1 activity of dextran sulfate and heparin, the dependence of this activity on the molecular weight and its relationship with anticoagulant activity, and, finally, the mechanism of anti-HIV-1 action of the compounds.
MATERIALS AND METHODS Cells. MT-4, a T4 lymphocyte line carrying human T-cell lymphotropic virus type I (HTLV-I) (12) , and HUT-78, a T4 lymphocyte line not carrying HTLV-I (13) , were used for the anti-HIV-1 assay. The cells were mycoplasma-negative. The cell lines used for the cytostasis assays-i.e., L1210, FM3A, Raji, Molt/4F, and CEM-have been described elsewhere (14, 15 /HTLV-IIIB cell cultures followed by filtration (0.45-,um pores) and ultracentrifugation (100,000 x g, 2 hr)]. The reaction was stopped with 200 ,u of trichloroacetic acid (5%, vol/vol) and the precipitated material was analyzed for radioactivity. For the MuLV reverse transcriptase assay, endogenous viral RNA served as the template. Otherwise, the assay conditions were as described previously (17) .
Virus Adsorption Assay. In the first experiment 2 x 106 MT-4 cells were suspended in medium (final volume, 100 ,ul) containing dextran sulfate (Mr 5000) or heparin at 25 ,ug/ml, after which 32,000 cpm of 32P-labeled HIV-1 was added. In the second experiment, 2 x 106 MT-4 cells were suspended in medium (final volume, 500 p1) containing dextran sulfate or heparin at 25 ,ug/ml, after which 11,000 cpm of 3H-labeled HIV-1 was added. The samples were incubated at 37°C, and after 0, 30, 60, or 120 min, the cells were collected by centrifugation (at 4°C) and washed three times with phosphate-buffered saline (Oxoid, Conforma, Belgium) (at 4°C) to remove unadsorbed virus particles. Then the cells were precipitated with 5% trichloroacetic acid, and acid-insoluble material was analyzed for radioactivity.
Dextran Sulfate Anticoagulant Activity Test. Anticoagulant activity of dextran sulfate was assessed by the standard methods for measuring the thrombin time and the activated partial thromboplastin time (APTT) of plasma containing the compound at various concentrations, as described previously (18, 19) . Anticoagulant activity of heparin and its fragments was expressed in international heparin units (IU).
RESULTS
Anti-HIV-1 Activity of Dextran Sulfate and Heparin. When dextran sulfate (Mr 5000) and heparin were evaluated for their inhibitory effect on the cytopathogenicity of HIV-1 in MT-4 cells, both compounds completely protected the cells against virus-induced destruction at a concentration of 25 ,ug/ml ( Fig. 1 ). At this concentration dextran sulfate and heparin inhibited virus antigen expression in HUT-78 cells by 85% and 74%, respectively (Fig. 1) . The 50% inhibitory concentrations (IC50) of dextran sulfate and heparin for HIV-1 replication measured by virus-induced destruction of MT-4 cells were 9.1 and 7.0 ,g/ml, respectively (Table 1) .
No cytotoxicity of the compounds for MT-4 cells, as measured by trypan blue exclusion, was noted at concentrations up to 3125 ,g/ml (dextran sulfate) or 625 ,g/ml (heparin) (Fig. 1 500,000) nor heparin proved inhibitory to MuLV-associated reverse transcriptase unless used at very high concentrations (237, >1000, and >400 ,ug/ml, respectively). Under the same conditions azidothymidine triphosphate showed an IC50 of 0.30 ug/ml for MuLV reverse transcriptase. These results indicate that dextran sulfate and heparin are not markedly inhibitory to reverse transcriptase whatever the origin of the enzyme (human or murine retroviruses).
Influence of Various Treatment Periods with Dextran Sulfate and Heparin on Their Anti-HlV-l Activity. In attempts to determine the mechanism of action of dextran sulfate and heparin on HIV-1 replication, various treatment periods with the compounds for MT-4 cells were examined. In treatment A, the cells were exposed to HIV-1 in the presence of the test compounds. After a 2-hr incubation at 37°C, both compound and unadsorbed virus were removed, and the cells were washed with culture medium and further incubated in the absence of the compounds. In treatment B, the cells were exposed to HIV-1, and after a 2-hr incubation at 37°C, unadsorbed virus was removed, and the cells were washed and further incubated in the presence of the compounds. Fig. 2A shows that treatment A with dextran sulfate (Mr 5000) was equally active as treatment B, and that treatment A combined with treatment B further enhanced the activity, so that complete protection was achieved at a compound concentration of 5 ,ug/ml. In marked contrast, treatment A with azidothymidine was approximately 1/100th as effective as treatment B, and the activity of azidothymidine was not further enhanced when the two treatment regimens were combined (Fig. 2B) . When heparin and dideoxycytidine were examined under the same conditions, heparin exhibited a behavior similar to that of dextran sulfate, whereas dideoxycytidine behaved similarly to azidothymidine. Treatment of the MT-4 cells with dextran sulfate or heparin for 24 hr, before the cells were infected with HIV-1 did not offer any protection ( Proc. Natl. Acad. Sci. USA 85 (1988) increased with the incubation time (Fig. 3) . When, however, dextran sulfate or heparin was added to the suspensions, little, if any, increase in cell-associated radioactivity was observed (Fig. 3) . These results indicate that dextran sulfate and heparin prevented the adsorption of HIV-1 to the MT-4 cells.
Anticoagulant Activity of Dextran Sulfate. When the anticoagulant activity of the dextran sulfates was examined, the thrombin time was found to be doubled with dextran sulfate (Mr 5000 or 8000) at a concentration of 50 ,ug/ml. Dextran sulfate ofMr 5000 caused a doubling ofthe APTT at 20 tkg/ml, whereas dextran sulfate of Mr 8000 did so at a concentration of 50 Ag/ml. At 10 ,ug/ml, which corresponds to the IC50 for HIV-1 replication in MT-4 cells (Table 1) , dextran sulfate (Mr 5000 or 8000) caused only a marginal prolongation of the APTT. Dextran sulfate of Mr 500,000 was the most potent anticoagulant, doubling the thrombin time and the APTT at 2 and 5 Ag/ml, respectively.
Inhibitory Effect of Fragmented Heparins on HIV-1 Replication. Since it has been demonstrated that the biological (i.e., anticoagulant) activity of heparin depends on its molecular weight (21) , the anti-HIV-1 and anticoagulant effects of various fragmented heparins with molecular weights ranging from 1400 to 11,000 were examined. activity. Both the antiviral and anticoagulant activity decreased with decreasing molecular weights of the heparin fragments. Dermatan sulfate did not exhibit either antiviral or anticoagulant activity (Table 3) .
DISCUSSION
The sulfated polysaccharides dextran sulfate and heparin are potent and selective inhibitors of HIV-1 replication in vitro (Fig. 1, Table 1 ). These compounds were also evaluated for their activity against other viruses and found to be effective against human immunodeficiency virus type 2, herpes simplex virus type 1 and type 2, and some other enveloped viruses (data not shown). The data presented in Table 2 indicate that, in all likelihood, dextran sulfate and heparin interfere with an early event of the virus replicative cycle, presumably virus adsorption. Full protective activity was achieved when the compounds were present only during the 2-hr virus adsorption period (Fig. 2) . No effect was seen when the compounds were incubated on the cells for 24 hr prior to virus infection (Table 2) , which suggests that they do not exert their anti-HIV activity indirectly, for example via induction of interferon or other lymphokines. Nor do they neutralize the virus directly, as established by experiments in which HIV-1 was incubated with the compounds before being inoculated on the cells.
As dextran sulfate and heparin were most effective when added to the cells during the virus adsorption period and thereafter [combined treatment A and B (Table 2) ], one may postulate that they interfere not only with the initial virus adsorption process but also with the subsequent virus adsorption stages as the virus goes through its successive cycles of replication. The virus is assumed to follow such multiple growth cycles because of the low multiplicity of infection used in our experiments.
The effect of dextran sulfate and heparin on the virus adsorption process was assessed directly, using radiolabeled HIV-1 particles. From Fig. 3 (23) . This concentration is considerably higher than the antivirally effective dose in vitro. In future clinical studies, it will be necessary to carefully monitor plasma levels of the compounds. This could be readily done on the basis of their anticoagulant activity (24) . Also, competitive binding assays could be designed to measure plasma concentrations of heparin and heparin derivatives (24) . Oral administration of the compounds may be feasible as shown before with heparin fragments in mice (25) .
In view of the high selectivity of heparin and dextran sulfate as inhibitors of HIV-1 replication in vitro, the selectivity of dextran sulfate (Mr 5000) exceeding that of azidothymidine (Table 1) , these polyanions should be further pursued for their potential in the prophylaxis and therapy of retrovirus infections in humans.
Note. During the time that this paper was under review, a report addressing, in part, the same subject was submitted by Mitsuya et al. Their published report (26) confirms the mechanism of action described above.
